Society of Hematologic Oncology Insider news – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

Society of Hematologic Oncology Insider news

SOHO Insider

Science

Frequency: 1 episode/20d. Total Eps: 15

SOHO Insider delivers on the latest news in hematologic oncology and updates from the Society of Hematologic Oncology

Site

RSS

Apple

Data updated on 01/10/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

https://sohoinsider.com/category/soho-insider-podcast/
6 shares
https://sohoinsider.com/category/meetings-conferences/soho-uk/
3 shares
https://soho.click/community-oncology-series
2 shares

https://pubmed.ncbi.nlm.nih.gov/41490516/
1 share

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 42%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

Dr. Roberto Mina on the pivotal phase 3 MajesTEC-9 trial in multiple myeloma

Friday, June 5, 2026 • Duration 05:51

In this SOHO Insider podcast, host Saad Usmani, MD, chief of the myeloma service at Memorial Sloan Kettering Cancer Center, spoke with Roberto Mina, MD, associate professor of hematology at Emory University, on news from the 2026 ASCO Annual Meeting.

The conversation highlighted a presentation by Dr. Roberto Mina regarding the pivotal phase 3 MajesTEC-9 trial evaluating teclistamab monotherapy for patients with relapsed/refractory multiple myeloma who were previously exposed to lenalidomide and anti-CD38 antibodies

Follow more news from ASCO here.

Read moreCollapse

Dr. Nirav Shah on the next iteration in CAR-T cell therapy in blood cancer

Thursday, May 7, 2026 • Duration 15:28

In this SOHO Insider podcast, host Megan Melody, MD, from Tampa General Hospital, spoke with Nirav Shah, MD, professor at the Medical College of Wisconsin, on news from the 2026 Tandem Meetings, including updates on dual-targeted CAR T-cell results in CLL and interim phase 2 data on zamtocabtagene autoleucel (zamto-cel) in in transplant-ineligible patients with DLBCL.

Of dual-targeting CAR-T cell therapies, he said, “I think this is the next iteration in CAR. Zamtocabtagene is one of four 20/19 CARs under development and if you look at the data for all of them, they look to be highly efficacious, better than our standard CD19-CAR.”

Listen to more podcasts on sohoinsider.com.

Read moreCollapse

Dr. Iacoboni on improving CAR T-cell therapy outcomes in lymphoma

Tuesday, March 17, 2026 • Duration 13:45

Gloria Iacoboni, MD, PhD, a hematologist at Vall d’Hebron University Hospital in Barcelona, Spain, spoke with Dr. James Day, a clinical research training fellow at UCL in London, during this SOHO Insider podcast episode recorded at the inaugural SOHO UK 2026 meeting. The meeting was held in London March 3 and 4 at the Royal College of Physicians in London.

Dr. Iacoboni discussed strategies to improve outcomes in high-grade lymphoma, focusing on improved patient selection, the emergence of dual-targeted CAR T-cell products (CD19/CD20), and how circadian rhythms might impact infusion efficacy.

Follow more news from SOHO UK.

Read moreCollapse

Why clinicians should lead hospitals, according to Prof. Amanda Goodall

Tuesday, March 10, 2026 • Duration 06:12

Prof. Amanda Goodall, director of the Executive Master’s in Medical Leadership (EMML), a specialized MSc degree from Bayes Business School offering advanced leadership training to medical doctors, joined SOHO Insider podcast host Prof. Christopher Fox, a professor of hematology at Nottingham University Hospitals NHS Trust, for a discussion on expert leadership in healthcare.

According to Prof. Goodall, expert leadership is the idea that organizations perform best when leaders are experts in the core work of the institution. As part of this work, she runs an executive master’s program in medical leadership, designed to help physicians develop the skills needed to lead healthcare organizations while maintaining credibility as clinicians.

Her research argues that in healthcare this means placing experienced, high-performing physicians in leadership roles rather than relying primarily on generalist managers. Many doctors, she noted, are interested in leadership because they want to drive meaningful change and improve patient care, but historically they have had limited access to formal leadership training.

The podcast was taped during the inaugural meeting of SOHO UK, where Prof. Goodall gave a talk after dinner on the topic.

Learn about the Executive Master’s in Medical Leadership (EMML) program.

Read moreCollapse

Prof. Cwynarski previews CNS, peripheral T-cell lymphoma sessions ahead of SOHO UK

Friday, February 27, 2026 • Duration 12:13

Prof. Kate Cwynarski, MD, PhD, joined SOHO Insider podcast host Megan Melody, MD, for a discussion previewing lymphoma sessions she will lead at the inaugural SOHO UK meeting, scheduled for March 3–4, 2026, in London.

Prof. Cwynarski will chair a “Meet the Expert” roundtable on challenges and controversies in managing central nervous system (CNS) lymphoma. The session will include a seven-year update of the MARIETTA study, which examined treatment strategies for secondary CNS lymphoma, as well as findings from a large real-world evidence study of secondary CNS lymphoma.

She will also lead a session on peripheral T-cell lymphoma focused on the shift toward biologically informed therapy. The presentation will highlight the TERZO study and explore how emerging biologic insights may guide treatment decisions in this heterogeneous group of lymphomas.

The sessions are part of the program for the first SOHO UK meeting, which will bring together global clinicians and researchers to discuss advances in the treatment of blood cancers.

Read moreCollapse

Public-private partnerships needed to sustain progress in blood cancer treatment

Monday, February 9, 2026 • Duration 03:31

John DiPersio, MD, PhD, current president of SOHO and director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine in St. Louis, Missouri, discusses the need for public-private partnerships to move novel therapies forward in the treatment of blood cancers. He also speaks about how cross-sector collaboration can create better research paths for the future.

For SOHO 2026, Dr. DiPersio chose the theme “Advancing care through collaborative science,” a timely topic as NIH funding continues to decline.

“SOHO 2026 will explore how public-private partnerships can sustain discovery, preserve basic research, and ensure access to innovation for patients around the world,” Dr. DiPersio said in a recent interview with SOHO Insider.

Register today for SOHO 2026 at soho.click/2026. SOHO members receive a 40% discount. Join SOHO for free at http://soho.click/join.

Read moreCollapse

Drs. Melody, Phillips talk glofitamab in MCL

Friday, January 30, 2026 • Duration 08:09

In this podcast episode recorded at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Megan Melody, MD, from Tampa General Hospital, spoke with Tycel J. Phillips, MD, from the City of Hope Cancer Center, on the latest advancements in mantle cell lymphoma (MCL), including the phase 1/2 trial in relapsed or refractory MCL recently published in the Journal of Clinical Oncology.

In the trial led by Dr. Phillips, the investigators evaluated glofitamab monotherapy in patients with relapsed or refractory B-cell lymphomas, with obinutuzumab pretreatment to mitigate the risk of cytokine release syndrome with glofitamab.

Dr. Phillips also spoke about treating patients with relapsed or refractory non-Hodgkin lymphoma with venetoclax.

Listen to other podcast episodes of SOHO Insider.

Read moreCollapse

Advances in essential thrombocythemia with Drs. Kuykendall, Tremblay

Friday, January 16, 2026 • Duration 17:04

In this episode of the SOHO Insider podcast, Andrew Kuykendall, MD, assistant member at Moffitt Cancer Center, and Douglas Tremblay, MD, assistant professor of medicine at Icahn School of Medicine at Mount Sinai, discuss how to approach the treatment of essential thrombocythemia.

“The first thing I do whenever a patient walks into the clinic with ET is think about their risk status,” Dr. Tremblay said. “When we speak about risk status, what we’re really speaking about is risk of thrombosis. There’s several different risk stratification methods, but they all rely on three clinical factors in general, which is age of prior thrombosis, which is probably the most potent risk factor.”

This episode also includes a discussion on the SURPASS-ET trial, which showed ropeginterferon alfa-2b outperformed anagrelide for disease control. Plus, a look into how new CALR-targeted antibodies improve bone marrow in early studies.

Dr. Masarova discusses SURPASS-ET study at EHA 2025

Read moreCollapse

Dr. Thomas Martin interviews 1st US patient treated with cilta-cel

Saturday, January 10, 2026 • Duration 09:48

In this episode of the SOHO Insider podcast, Thomas Martin, MD, professor of medicine at University of California, San Francisco, talks with patient Craig Chase, an American father of two who was diagnosed with myeloma in 2014; Chase was the only American to travel to Nanjing, China, in 2017 to receive ciltacabtagene autoleucel (cilta-cel; then LCAR-B38M).

Chase shares his experience traveling to China for the therapy as a heavily-treated patient with limited treatment options. Chase talked about his treatment journey, his experience being treated in a foreign country with an experiment therapy, and what it was like achieving long-term remission.

Dr. Martin also discussed the five-year CARTITUDE-1 follow-up date presented at both ASCO(R) and EHA 2025. Those date showed that one-third of myeloma patients were in remission more than five years after cilta-cel treatment. The results of these trials and other trial data on therapies other than cilta-cel, prompted Sundar Jagannath, MD, during SOHO 2025 to address the potential of using the word cure when speaking with patients.

Read moreCollapse

Tara Graff, DO, talks community care and the CAR-T vs bispecific debate

Thursday, November 27, 2025 • Duration 24:22

SOHO Insider lymphoma podcast host Megan Melody, MD, assistant professor at the University of South Florida, interviews Tara Graff, DO, director of clinical trials and lymphoma specialist at Mission Cancer and Blood, part of University of Iowa Health Care, on treating patients with blood cancers in community settings, and whether the future belongs to bispecific antibodies or CAR-T therapies.

“To be able to give your patients these novel therapies is amazing,” Dr. Graff said on the podcast. “I think it’s going to be a bispecific-versus-CAR-T world in all the different disease states of lymphoma. But I don’t think I would choose one or the other across the board.”

They also discussed how hematologist-oncologists can support colleagues who have not managed toxicities associated with cell therapies.

“I think we’re just going to have to be patient and really help, because if we don’t help them, all the specialists are going to wind up seeing all the other specialties’ patients,” Dr. Graff said. “And there’s no way we can do that. It’s just being patient and helping each other.”

Listen to more SOHO Insider podcasts.

Read moreCollapse

Society of Hematologic Oncology Insider news – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Society of Hematologic Oncology Insider news – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

Other24

PubMed1

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

Related Shows Based on Content Similarities

Other24

PubMed1